P1375: VENETOCLAX MODULATES TIM-3 EXPRESSION ON CD8 T CELLS IN ACUTE MYELOID LEUKEMIA PATIENTS

P1375: VENETOCLAX MODULATES TIM-3 EXPRESSION ON CD8 T CELLS IN ACUTE MYELOID LEUKEMIA PATIENTS

Bibliographic Details
Main Authors:	Darina Ocadlikova, Giulia Corradi, Dorian Forte, Gianluca Cristiano, Michele Cavo, Antonio Curti
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000972388.97655.cf

Similar Items

Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance?
by: Marilena Ciciarello, et al.
Published: (2021-10-01)

A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine
by: Darina Ocadlikova, et al.
Published: (2020-09-01)

Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach
by: Alessandro Isidori, et al.
Published: (2018-06-01)

Venetoclax Resistance in Acute Myeloid Leukemia
by: Sylvain Garciaz, et al.
Published: (2024-03-01)

Venetoclax in adult acute myeloid leukemia
by: Mengci Hu, et al.
Published: (2023-12-01)

PB1795: MESENCHYMAL STROMAL CELL-DEPENDENT ADHESION PATHWAYS PROTECT AML CELLS FROM VENETOCLAX-INDUCED APOPTOSIS
by: Marilena Ciciarello, et al.
Published: (2023-08-01)

Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
by: Simona De Gregori, et al.
Published: (2023-06-01)

Biomarkers of Response to Venetoclax Therapy in Acute Myeloid Leukemia
by: Carlos Rodríguez-Medina, et al.
Published: (2024-01-01)

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies
by: Mila S. Griffioen, et al.
Published: (2022-07-01)

Targeted activation of GPER enhances the efficacy of venetoclax by boosting leukemic pyroptosis and CD8+ T cell immune function in acute myeloid leukemia
by: Jun Ren, et al.
Published: (2022-10-01)

Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
by: Renshi Kawakatsu, et al.
Published: (2024-02-01)

Clinical Study of Venetoclax with Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
by: CHEN Xiaofeng, WANG Meng, LI Zhongyu, LI Jiajia
Published: (2022-03-01)

Research progress of anti-apoptotic inhibitor venetoclax in treatment of myeloid leukemia
by: XIANG Caixia, HUANG Bintao, HAO Jian
Published: (2023-05-01)

Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia
by: Emmanuella Oyogoa, et al.
Published: (2023-07-01)

Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
by: Serena Brancati, et al.
Published: (2021-12-01)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
by: Ian M. Bouligny, et al.
Published: (2023-05-01)

P558: ABSOLUTE LYMPHOCYTE COUNT IS AN INDEPENDENT SURVIVAL PREDICTOR COMPARED TO MINIMAL RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY
by: Gianluca Cristiano, et al.
Published: (2023-08-01)

Upregulation of Tim‐3 is associated with poor prognosis in acute myeloid leukemia
by: Zhengwei Wu, et al.
Published: (2023-04-01)

Venetoclax Combination Treatment of Acute Myeloid Leukemia in Adolescents and Young Adult Patients
by: Elena Chatzikalil, et al.
Published: (2024-04-01)

PB1840: MONOCENTRIC EXPERIENCE OF VENETOCLAX-BASED REGIMENS FOR ACUTE MYELOID LEUKEMIA
by: M. Sciumè, et al.
Published: (2022-06-01)

P476: AN ORAL COMBINATION THERAPY OF OR-2100 AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA
by: Kazuharu Kamachi, et al.
Published: (2023-08-01)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
by: Xi Xu, et al.
Published: (2023-10-01)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
by: Baohang Zhang, et al.
Published: (2023-05-01)

Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia
by: Mariarita Sciumè, et al.
Published: (2023-03-01)

BCL-2 inhibitor venetoclax-innovating the therapeutic pattern of acute myeloid leukemia
by: WANG Xiaoling, et al.
Published: (2023-08-01)

Repurposing ribosome-targeting antibiotics to overcome resistance to venetoclax in acute myeloid leukemia
by: David Sharon, et al.
Published: (2020-03-01)

An integrative systems biology approach to overcome venetoclax resistance in acute myeloid leukemia.
by: Michelle Przedborski, et al.
Published: (2022-09-01)

Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience
by: Adriana Trabal, et al.
Published: (2023-03-01)

PB1861: EFFICACY AND TOXICITY OF VENETOCLAX PLUS HYPOMETHYLATING AGENTS IN THE REAL LIFE OF ACUTE MYELOID LEUKEMIA
by: Gianluca Martini, et al.
Published: (2023-08-01)

Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia
by: Claudia Tregnago, et al.
Published: (2022-01-01)

Clinical efficacy of azacytidine and venetoclax and prognostic impact of Tim-3 and galectin-9 in acute myeloid leukemia and high-risk myelodysplastic syndromes: A single-center real-life experience
by: Valentina Giudice, et al.
Published: (2022-12-01)

P522: ABSOLUTE LYMPHOCYTE COUNT IS AN INDEPENDENT SURVIVAL PREDICTOR IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY
by: G. Cristiano, et al.
Published: (2022-06-01)

Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia
by: Jingying Cui, et al.
Published: (2024-12-01)

P524: PHARMACODYNAMICALLY DEFINED METRONOMIC DOSING OF DECITABINE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA
by: Kateryna Fedorov, et al.
Published: (2023-08-01)

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
by: Sylvain Garciaz, et al.
Published: (2022-04-01)

Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
by: Jorge Labrador, et al.
Published: (2022-03-01)

The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions
by: Matteo Piccini, et al.
Published: (2023-05-01)

Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome
by: Mohammad Houshmand, et al.
Published: (2021-03-01)

Infections of Venetoclax-Based Chemotherapy in Acute Myeloid Leukemia: Rationale for Proper Antimicrobial Prophylaxis
by: Raeseok Lee, et al.
Published: (2021-12-01)

Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
by: Leiming Xia, et al.
Published: (2023-05-01)